Product Description
Pegylated Somatropin. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT02976675)
Mechanisms of Action: GHR Replacer
Novel Mechanism: Yes
Modality: Coagulation Factor
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Changchun GeneScience Pharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Dwarfism, Pituitary
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06007417 |
ELEVATE | P3 |
Unknown status |
Dwarfism, Pituitary |
2025-05-01 |
9% |
2025-10-01 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|